Curis FDA Removes Partial Clinical Hold On TakeAim Leukemia Study

WASHINGTON (dpa-AFX) – Curis, Inc., (CRIS) announced the FDA has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. On April 4, 2022, the FDA placed a partial clinical hold on the study. Also, the recommended phase 2 dose for emavusertib as a monotherapy has…Read More